Background. The reclassification of noninvasive encapsulated follicular variant of papillary thyroid cancer to noninvasive follicular thyroid neoplasm with papillary-like nuclear features will reduce nonefficacious and potentially harmful care. Reclassification is estimated in 18.6% of patients with papillary thyroid carcinoma; we aimed to quantify the implications of this change. Methods. Pathology reports from April 2006 to April 2016 were reviewed to isolate cases that would have been designated as neoplasm with papillary-like nuclear features. Of the 1,335 cases of papillary thyroid carcinomas, 194 cases (14.5%) met criteria. Cases in which neoplasm with papillary-like nuclear features was found in combination with other thyroid malignancies (n = 25) and cases of prior thyroid lobectomy (n = 5) were excluded. Demographic, pathologic, treatment, and follow-up data were assessed for the remaining 164 potential neoplasm with papillary-like nuclear features cases. Logistic regression analysis was performed to evaluate association between fine-needle aspiration result and index procedure. Results. Of the 164 patients with tumors who met neoplasm with papillary-like nuclear features criteria, fine-needle aspiration results were nondiagnostic (2%), benign (18%), atypia/follicular lesion of undetermined significance (26%), follicular neoplasm or suspicious for follicular neoplasm (20%), suspicious for malignancy (19%), malignant (6%), and not obtained (9%). Eighty-five (52%) patients underwent total thyroidectomy. A "suspicious for malignancy" fine-needle aspiration result was associated with undergoing total thyroidectomy versus thyroid lobectomy (P = .006). Thyroid lobectomy was the index procedure for 79 patients (48%); of these patients, 54% (n = 43, 3.2% of all patients with papillary thyroid carcinomas) underwent subsequent total thyroidectomy, and 24% received postoperative radioactive iodine treatment. There were no recurrences among the 125 patients with >3 months of follow-up. Conclusion. The reclassification of noninvasive encapsulated follicular variant of papillary thyroid cancer as neoplasm with papillary-like nuclear features will decrease nonefficacious treatment and reduce costs. However, the impact of this change with regard to extent of surgery was limited to 3.2% of patients with papillary thyroid carcinomas compared with the projected potential impact on 18.6%.
The increase in the incidence of thyroid cancer is attributable largely to an increase in the diagnosis of small papillary thyroid carcinomas (PTC) 4, 5 and specifically to an increase in diagnosis of a variant of PTC known as the follicular variant of PTC (FVPTC), which comprises >25% of all PTCs. 6, 7 Two main subsets of FVPTC include infiltrative FVPTC, which are more likely to harbor BRAF mutations and have a higher prevalence of lymph node metastasis and local recurrences, 8 and encapsulated FVPTC (EFVPTC), which are more likely to have mutations in the RAS family of oncogenes and have a low recurrence rate in the absence of capsular or vascular invasion. 9 Throughout the past decade, multiple studies have demonstrated that noninvasive EFVPTC has an indolent course and is genetically distinct from infiltrative tumors, 8, [10] [11] [12] [13] yet it had been treated similarly to conventional PTC.
A landmark study published in April 2016 proposed that PTCs thus far diagnosed as noninvasive EFVPTC should now be entitled noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), reclassifying a cancer as a indolent tumor.
14 This reclassification intends to reduce nonefficacious and potentially harmful treatments and follow-up and to reduce the psychologic burden associated with a cancer diagnosis.
14 It is estimated this reclassification would affect >46,000 patients, or 18.6% of the 250,000 patients diagnosed with papillary PTC worldwide each year, 14 and about 10,000 (15.4%) of the nearly 65,000 thyroid cancer patients per year in the United States. 15 Theoretically, the reclassification of noninvasive EFVPTC to NIFTP should result in fewer total thyroidectomies because thyroid lobectomy alone is sufficient in the work-up and management of NIFTP given the indolent nature of these lesions. However, the surgical impact is largely only relevant when the indication for surgery is the NIFTP itself, rather than when NIFTP is found incidentally and thyroid surgery is performed for other reasons. In our study, we aimed to help quantify the implications of the reclassification of noninvasive EFVPTC to NIFTP by examining 10 years of thyroid cancer data from a single academic medical center. Our center is equipped to do this retrospectively because our pathologists have been reporting noninvasive EFVPTC for the duration of the study by systematically analyzing the tumor capsule. Given that a significant number of patients with NIFTP undergo total thyroidectomy as their index procedure (rather than thyroid lobectomy) for various reasons, we hypothesized that the impact of this reclassification on extent of surgery in our cohort would be less than previously projected.
Methods

Study cohort and inclusion criteria
A natural language search of pathology reports from April 2006 to April 2016 from a single academic medical center, Massachusetts General Hospital, was performed to identify cases of noninvasive EFVPTC that would have been designated as NIFTP. Of the 1,335 cases of PTC, there were 279 cases of EFVPTC; of these, there were 76 cases of infiltrative EFVPTC and 203 cases of noninvasive EFVPTC. Of the 203 cases of noninvasive EFVPTC, 194 cases met established pathologic NIFTP criteria [(1) thick, thin, or partial capsule or well circumscribed with a clear demarcation from adjacent thyroid tissue; (2) follicular growth pattern; (3) unequivocal nuclear changes of PTC; (4) absence of capsular or vascular invasion, and (5) capsule submitted in its entirety]. Tumors with insufficient nuclear changes for the diagnosis of PTC did not receive the diagnosis of noninvasive EFVPTC because they would not have met criterion (3) . Cases in which NIFTP was found in combination with other thyroid malignancies (n = 25) and cases of prior thyroid lobectomy (n = 5) were excluded. Cases that met the inclusion criteria were confirmed by an endocrine pathologist (P.M.S.).
Covariates and data analysis
Clinical information was abstracted retrospectively from the electronic medical record in compliance with the medical center's institutional review board. The following information was collected for the 164 potential NIFTP cases: patient demographic information (including sex and age at time surgery in years as a continuous variable); preoperative FNA diagnosis [as classified by the Bethesda System for Reporting Thyroid Cytopathology FNA as (1) nondiagnostic, (2) benign, (3) follicular lesion or atypia of undetermined significance [FLUS and AUS, respectively], (iv) follicular neoplasm [FN] or suspicious for FN, (5) suspicious for malignancy, and (6) malignant]; procedure type (total thyroidectomy versus thyroid lobectomy); and tumor characteristics (including size in centimeters as a continuous variable, Afirma Gene Expression Classifier testing when available, and tumor focality as a categorical variable categorized as unilateral tumors, multiple unilateral tumors, or bilateral tumors). Additionally, we collected data on follow-up interventions, including completion thyroidectomy (if a patient had thyroid lobectomy as their index procedure) and postoperative radioactive iodine (RAI) treatment status (both binary variables), median follow-up times from index surgical procedure (in months as a continuous variable), and recurrence status (binary variable). We defined recurrence of disease as new, structural PTC verified by cytology of an FNA biopsy or on formal surgical pathology in a previously treated patient, with a clinical disease-free interval (ie, on physical examination, neck ultrasound).
Continuous variables were reported as mean ± standard deviation or median with interquartile range and categorical variables were reported as percent frequency (%). Univariate analysis of whether index procedure was associated with FNA result, sex, age, and tumor size was performed, using the appropriate test (Student t test and Fisher exact test) when comparing group means or frequencies. To evaluate whether FNA result was associated with undergoing total thyroidectomy as the index operation, a multivariable logistic regression was performed with a benign result as the reference group. Additional covariates included age as a continuous variable and tumor size as a continuous variable. Statistical analysis was performed using STATA version 12 (STATA Corp., TX).
Results
Cohort characteristics are outlined in Table I . Of the 164 patients with tumors meeting NIFTP criteria, 130 (79%) were women. The mean age of patients was 50 ± 15 years, and the mean index tumor size was 2.0 ± 1.5 cm. The American Joint Committee on Cancer 7th edition tumor-stage of these tumors included 1a (33%), 1b (23%), 2 (34%), and 3 (10%). Most had solitary tumors (n = 143), while 21 patients had multifocal NIFTP (12 ipsilateral, 9 bilateral). As per the Methods, 25 cases in which NIFTP was found in combination with 
17 (10.4) other thyroid malignancies were excluded; thus, these cases were not counted in the multifocal NIFTP group. Fine-needle aspiration (FNA) results from the primary tumor focus (Table II) were nondiagnostic (2.4%), benign (18.3%), atypia/follicular lesion of undetermined significance (25.6%), FN (20.1%), suspicious for malignancy (18.9%), malignant (5.5%), and absent (9.2%). Patients who did not undergo preoperative FNA were those who underwent surgery primarily for symptomatic multinodular goiter (n = 13) or hyperthyroidism (n = 2); thus, in these cases, NIFTP was essentially found incidentally.
Total thyroidectomy was performed in 30% of those with a benign FNA (Table III) ; in these cases, surgery was performed primarily for an enlarging nodule or symptomatic multinodular goiter. Total thyroidectomy was also performed in 19/42 patients with AUS or FLUS samples (45.2%), 13/33 patients with FN or suspicious for FN samples (39.4%), 22/31 patients with samples suspicious for malignancy (71%), and 9/9 patients with FNA samples demonstrating definitive malignancy (Table III) . On unadjusted analysis, differences in age and index tumor size were statistically significant between those who underwent thyroid lobectomy versus total thyroidectomy as the index procedure (46.6 ± 14.0 years vs 53.6 ± 15.2 years and 2.4 ± 1.4 vs 1.7 ± 1.5 cm, respectively). Index tumor size was smaller in the total thyroidectomy group given that this group included more incidentally found NIFTPs, frequently when the surgical indication was symptomatic multinodular goiter. Afirma Gene Expression Classifier testing was only recorded for 9 patients in the NIFTP cohort; of these patients, 1 had a benign result and 8 had a suspicious result. Of the 8 patients with a suspicious result, 5 patients underwent total thyroidectomy and 3 patients underwent thyroid lobectomy.
A multivariable logistic regression was performed to evaluate whether FNA result was associated with a patient undergoing total thyroidectomy (versus thyroid lobectomy; Table IV ). After adjusting for age and tumor size, a "suspicious for malignancy" FNA result (versus a benign result) was found to be independently predictive of undergoing total thyroidectomy versus thyroid lobectomy (odds ratio, 4.90; P = .006).
Overall, of the 1,335 patients diagnosed with PTC from April 2006 to April 2016, 79 NIFTP patients (6%) underwent thyroid lobectomy and 85 (6.4%) underwent total thyroidectomy as their index procedure (Fig) . Of the 79 patients who underwent thyroid lobectomy as their index procedure (48% of the cohort), 54% (n = 43) underwent subsequent total thyroidectomy and 24% (n = 19) received postoperative RAI treatment after completion thyroidectomy. Thus, of the 1,335 patients with PTC, 43 patients (3.2%) would have had the potential for less extensive surgery after the reclassification of noninvasive EFVPTC to NIFTP. Of those who underwent thyroid lobectomy as their index procedure, 15 (19%) underwent this procedure for a reason other than FNA findings, including lobectomy for multinodular goiter or symptomatic mass, parathyroid adenoma exploration, and thyroid lobectomy in the setting of surgery for thyroglossal duct cyst excision.
Eighty-five NIFTP patients underwent total thyroidectomy as their initial procedure (Fig) ; of these patients, 29 (34%) underwent this procedure for a reason other than FNA findings (ie, the patient had a benign FNA but a symptomatic multinodular goiter). Twentyfour percent of the total thyroidectomy group underwent * Patients who did not undergo preoperative FNA were those who underwent surgery for symptomatic multinodular goiter (n = 13) or hyperthyroidism (n = 2). * Given that all patients with malignant FNA cytology results underwent total thyroidectomy, these patients (n = 9) were omitted from the model. 
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Discussion
In 2016, it was proposed that noninvasive EFVPTCs no longer be classified as "cancer" and instead be called NIFTP. 14 It is projected that this name change will affect >46,000 patients, or 18.6% of the 250,000 patients diagnosed with PTC worldwide each year 14 and about 10,000 (15.4%) of the nearly 65,000 thyroid cancer patients per year in the United States. 15 In this study, we aimed to help quantify the implications of this change in terms of extent of surgery by examining 10 years of thyroid cancer data from a single academic medical center. In our cohort, given that only half of patients underwent lobectomy as their index procedure, and only half of these patients underwent subsequent completion thyroidectomy, the potential impact of this change with regard to extent of surgery was limited to approximately 3.2% of patients with PTC compared with the projected potential impact on 18.6% of all patients with PTC worldwide.
The determination of NIFTP still requires examination of the entire tumor capsule. Moreover, patients still require at least a thyroid lobectomy for diagnosis. Therefore, the impact of an NIFTP diagnosis will largely be borne out of less extensive surgery, namely thyroid lobectomy versus total thyroidectomy. Rosario et al performed a retrospective study 16 examining potential NIFTP cases at a single institution. In their study of 129 potential NIFTP patients, approximately 50% underwent thyroid lobectomy as their index procedure, similar to our rate of 48%. This again highlights that even if NIFTP is diagnosed on final pathology, the potential to avoid further surgical intervention may only affect approximately half of patients.
In our study, of the 48% of patients who underwent thyroid lobectomy as the index procedure, only about half underwent subsequent total thyroidectomy; in most of these cases, patients were counseled on the low-risk nature of their tumors and ultimately opted for lobectomy alone with surveillance. This trend toward more conservative surgical treatment is in line with the 2015 American Thyroid Association thyroid nodule and differentiated thyroid cancer management guideline recommendations, which suggest lobectomy alone as a reasonable surgical approach in low-risk PTC. 17 With regard to the other half of patients who underwent total thyroidectomy as their index procedure, it was clear that patients undergo total thyroidectomy initially for a variety of reasons that will not be affected by the nomenclature change to NIFTP. In our cohort, 34% of patients who underwent total thyroidectomy underwent the procedure for a reason other than a concerning FNA result, such as for symptomatic multinodular goiter, compressive symptoms, other nearby head and neck cancer, and Grave's disease. Thus, because NIFTP is often found incidentally on final pathology after a total thyroidectomy, it is important not to include these patients in the projected surgical impact of the nomenclature change because these patients would have received the same operation regardless of the NIFTP diagnosis.
We acknowledge that the impact of this reclassification, and consideration of a once-cancer as now an indolent tumor, extends beyond saving patients from undergoing completion thyroidectomy after thyroid lobectomy. For one, we found that 39 patients in our cohort (24% of our NIFTP patients) underwent postoperative RAI treatment. RAI has its own expense and complications, [18] [19] [20] and eliminating the use of this treatment in this population will be significant. Other considerations include the psychologic impact of a cancer diagnosis 21, 22 and the cost and toll associated with longterm clinical follow-up given that PTC can recur up to 30 years after diagnosis. 23 In fact, Likhterov et al found that the total direct and indirect costs of surveillance of a patient with EFVPTC in 2015 approximates $4,388 for the first year after surgery and $3,884 for each subsequent year of surveillance. 24 At the same time, we must also consider the immediate logistical cost of disclosure to many patients that their malignant pathology has been reclassified as "nonmalignant," and we must consider the cost of reevaluating the pathologic slides of those patients at risk to ensure that the invasive nature of the tumor is comprehensively evaluated before notifying the patient of a change in diagnosis. 24 In many cases, this reclassification may not be possible if the capsule was not entirely submitted for evaluation initially and if slides are not available for review; it may also carry medicallegal considerations. A future comprehensive direct and indirect comparative effectiveness analysis of the change in thyroid nodule management, after the nomenclature change to NIFTP, will be especially important to further quantify the overall impact on patients, clinicians, and society.
This study has inherent limitations secondary to the retrospective nature of its design. We utilized pathology reports of FVPTC alone in identifying patients for the study. There is, therefore, the potential for misdiagnosis. Prospective data collection and analysis after the April 2016 change will be important as we continue to better understand the implications of this reclassification. Second, we did not routinely perform molecular tests on our pathology samples; this information would have been instructive because previous studies have shown that mutations in BRAF are not expected in NIFTP, whereas mutations in RAS are common. 14 Although Afirma Gene Expression Classifier testing was only performed for 9 patients in our proposed NIFTP cohort, a majority (8/9) of these patients had a suspicious result, consistent with prior research demonstrating that noninvasive FVPTCs are often categorized as suspicious by Afirma Gene Expression Classifier testing. 25 This highlights that, to date, preoperative Afirma Gene Expression Classifier testing and FNA do not aid in diagnosing NIFTP. A suspicious result on Afirma Gene Expression Classifier testing may, in fact, lead surgeons and patients to choose total thyroidectomy as the initial procedure. In terms of FNA results, in our cohort, a "suspicious for malignancy" result (versus a benign result) was found to be independently predictive of undergoing total thyroidectomy versus thyroid lobectomy. Although this will vary with institution, surgeon, and over time with changing guidelines and a shift to less aggressive therapy, many surgeons will treat "suspicious for PTC" as malignant and perform total thyroidectomy per usual care. This is underscored by the finding that all patients with malignant FNA in our cohort underwent total thyroidectomy. Lastly, although there were no cases of recurrence among the patients in our cohort, our median follow-up time was only 2 years. This short median follow-up time was due to a number of factors, including the number of patients in our cohort being diagnosed and treated in the past 5 years as well as patients relocating or becoming lost to follow-up in our system. It will be important to continue to track long-term recurrence rates of NIFTP moving forward.
The overall low mortality associated with thyroid cancer should be complemented by minimal morbidity from diagnosis and treatment. In this vein, the recent reclassification of noninvasive EFVPTC to NIFTP will likely improve the quality of thyroid cancer care and the quality of life of the affected patients and reduce costs. However, this impact may be more limited than previously predicted. In our cohort, given that only 48% of patients underwent lobectomy as their index procedure, and only half of these patients underwent completion thyroidectomy, the potential impact of the nomenclature change with regard to extent of surgery was limited to approximately 3.2% of all patients with PTC compared with the projected potential impact on 18.6% of patients with PTC. Future studies that characterize the molecular and clinical features of NIFTP and further evaluate the impact of this reclassification on overall treatment, surveillance, and quality of life will be instructive. Number 2, per your cytology, 6% were reported as papillary carcinoma. That means that 6% had a false-positive, if you take NIFTP. And I'm just curious, how do you explain to the pathologist or the patients that the false-positive rate is generally 1 percent, but when it comes to NIFTP, it is 6 percent? And the last question I have is, you have several patients who received RAI. The whole idea of NIFTP is to avoid RAI. Why did you decide to give RAI to these patients? Thank you.
Thank you. Dr Rajshri Mainthia: Thank you. Those are all great questions. So I'll start in terms of counseling patients. At this point, we definitely do counsel patients on the indolent nature of these tumors and that really no further treatment is indicated. Similarly, as patients return to clinic who are curious about an existing diagnosis that is now considered NIFTP, we also let them know about the indolent nature of these tumors. Unfortunately, in many cases retrospective reclassification is not possible when the capsule was not entirely submitted initially and when slides are not available for review.
With regard to the cytology results and 6% being malignant, that certainly is a high false positive rate. This highlights the potential role of more thorough pre-operative FNA analysis. We know that a NIFTP diagnosis requires evaluation of the entire capsule. That said, Strickland et al were able to at least distinguish NIFTP/FVPTC from classical PTC in 94% of their FNA samples by assessing a number of histological features such as follicular architecture. It is hard not to go to surgery with a malignant FNA result so this type of extra pre-operative analysis could decrease the false positive rate.
With regard to RAI, I would say that over the course of the 10 years for which we studied these patients, RAI became less popular in recent years, in line with the general trend toward more conservative treatment and the gradual recognition of the indolent nature of these tumors. So of the 24% of patients in our NIFTP cohort who underwent RAI treatment, a majority of cases were from the first half of the study period. Now, of course, patients with this diagnosis would not be offered RAI treatment.
Dr Kepal N. Patel (New York, NY): Great talk. Expanding on what you just said, did you analyze your cohort of patients during different time periods? Based on the most recent ATA guidelines, a thyroid lobectomy for papillary thyroid cancer is reasonable, and thus the incidence of completion thyroidectomy should probably decrease. Did you see a decrease in completion thyroidectomy regardless of NIFTP reclassification? Did the number of completion thyroidectomies change during different time periods of the study based on the changes in the ATA guidelines, regardless of NIFTP reclassification? Dr Rajshri Mainthia: Right. That's a great question. There actually wasn't as significant difference in the number of total thyroidectomies performed throughout the study period. This could be because of our small n, but could also be because patients underwent total thyroidectomy versus thyroid lobectomy for a variety of reasons that were not affected by the 2015 ATA guidelines, such as in the setting of multinodular goiter or an enlarging compressive nodule. In these cases, NIFTP (or PTC at the time) was essentially an incidental post-operative finding.
Dr Martha A. Zeiger (Baltimore, MD): I congratulate you on an excellent presentation. I just have a simple question that I would like you to address. Why not look at the impact of this diagnosis within the diagnosis of FVPTC rather than all of PTC? Because most PTC we can diagnose with FNA, and I don't really think that this is a challenge preoperatively.
Dr Rajshri Mainthia: Yes, that's a great question. When we were trying to isolate the cases of noninvasive encapsulated follicular variant of PTC, we did first look at overall follicular variants and then teased out the encapsulated subset. Even within the encapsulated subset, there is a noninvasive and invasive group. Separate analyses of these groups would be very interesting to do in the future.
The scope of this study was to really focus in on the ones that would have been diagnosed as NIFTP and further characterize them.
Dr Sally Carty (Pittsburgh, PA): Lovely paper. Very nice presentation. To answer Dr Shaha, when the patient asks, "Is this cancer?" we say, "Maybe." It's a premalignant diagnosis or tumor that requires surgery for diagnosis, and the only thing that's likely to die is the binary thinking of benign versus malignant. It needs to go by the wayside. We need a third category, just like in breast, DCIS.
So how do you code this at your institution? Do you code it as benign or malignant, or do you call for change? Dr Rajshri Mainthia: I think we will need to call for a change. Regarding coding, I would defer to any of the endocrine surgeons at our institution. I'm not completely sure. I agree that this is an indolent tumor, but not a benign tumor, which is such an important point. There should be a third category.
